Adenine base editing in an adult mouse model of tyrosinemia. Humans; mice
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Genome editing in adult mice to cure tyrosinemia
应用场景：
创建时间：
2019-01-07
相关数据集
Repairing pathogenetic mutations using engineered Prime Editor in vivo
We attempted to repaire genetic mutaions that cause hereditary heart disease using engineered Prime Editing in vivo.
NIAID Data Ecosystem50
Ex vivo therapeutic base and prime editing using chemically derived hepatic progenitors in a mouse model of tyrosinemia type 1. Kim et al.
Bipotent differentiation capacity of HT1-mCdHs. (A) Gene expression levels of mature hepatocyte-specific markers determined by RT-qPCR. Gapdh was used as an internal control. Data are mean ± SD (n=9).
NIAID Data Ecosystem50
TYROSINEMIA TYPE III: A CASE REPORT OF SIBLINGS AND LITERATURE REVIEW
ABSTRACT Objective: Tyrosinemia type III (HT III) is the rarest form of tyrosinemia, and the full clinical spectrum of this disorder is still unknown. The neurological involvement varies, including
NIAID Data Ecosystem40
Precise correction of heterozygous SHOX2 mutations in hiPSCs derived from patients with atrial fibrillation via genome editing and sib-selection
Patient-specific human induced pluripotent stem cells (hiPSCs) offer unprecedented opportunities for the investigation of multigenic disease, personalized medicine, and stem cell therapy. For heteroge
NIAID Data Ecosystem50
BEST1 mutation correction
In this study, we identified a homozygous deep intron variation (DIV), c.867+97G>A, in a case of ARB that exhibits atypical clinical features. Furthermore, ABE was harnessed for the targeted gene corr
NIAID Data Ecosystem40
